VEA
TBPH icon

Virtus ETF Advisers’s Theravance Biopharma TBPH Stock Holding History

Virtus ETF Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
9,557
+457
+5% +$7.57K 0.06% 310
2026
Q1 		$148K Hold
9,100
– – 0.07% 292
2025
Q4 		$170K Buy
+9,100
New +$151K 0.08% 276
2025
Q1 		– Sell
-35,426
Closed -$333K – 761
2024
Q4 		$333K Sell
35,426
-2,960
-8% -$26.9K 0.14% 224
2024
Q3 		$309K Hold
38,386
– – 0.14% 228
2024
Q2 		$326K Buy
38,386
+3,779
+11% +$34.1K 0.16% 216
2024
Q1 		$310K Buy
34,607
+4,979
+17% +$46.1K 0.16% 225
2023
Q4 		$333K Buy
29,628
+396
+1% +$3.99K 0.21% 202
2023
Q3 		$252K Sell
29,232
-3,777
-11% -$36.5K 0.15% 224
2023
Q2 		$342K Buy
33,009
+5,537
+20% +$61.1K 0.2% 163
2023
Q1 		$298K Buy
27,472
+483
+2% +$5.11K 0.16% 218
2022
Q4 		$303K Sell
26,989
-520
-2% -$5.46K 0.16% 263
2022
Q3 		$279K Buy
27,509
+400
+1% +$3.75K 0.11% 282
2022
Q2 		$246K Sell
27,109
-9,250
-25% -$85.2K 0.09% 301
2022
Q1 		$348K Hold
36,359
– – 0.16% 159
2021
Q4 		$402K Buy
36,359
+11,957
+49% +$104K 0.15% 146
2021
Q3 		$181K Sell
24,402
-2,241
-8% -$25.1K 0.08% 296
2021
Q2 		$387K Sell
26,643
-6,228
-19% -$117K 0.16% 195
2021
Q1 		$671K Buy
32,871
+905
+3% +$17.2K 0.28% 112
2020
Q4 		$568K Buy
31,966
+8,818
+38% +$158K 0.24% 128
2020
Q3 		$342K Buy
23,148
+1,950
+9% +$36.5K 0.18% 194
2020
Q2 		$445K Sell
21,198
-5,745
-21% -$148K 0.21% 165
2020
Q1 		$623K Sell
26,943
-2,273
-8% -$56.9K 0.26% 146
2019
Q4 		$756K Sell
29,216
-14,226
-33% -$276K 0.12% 152
2019
Q3 		$846K Sell
43,442
-7,309
-14% -$148K 0.17% 153
2019
Q2 		$829K Buy
50,751
+22,139
+77% +$449K 0.17% 179
2019
Q1 		$649K Buy
28,612
+6,169
+27% +$156K 1.38% 22
2018
Q4 		$574K Sell
22,443
-9,783
-30% -$264K 0.1% 57
2018
Q3 		$1.05M Buy
32,226
+2,171
+7% +$59.2K 0.11% 47
2018
Q2 		$682K Sell
30,055
-2,934
-9% -$69.7K 0.6% 106
2018
Q1 		$800K Sell
32,989
-1,940
-6% -$53.3K 0.69% 72
2017
Q4 		$974K Buy
34,929
+7,283
+26% +$216K 1.22% 26
2017
Q3 		$947K Hold
27,646
– – 0.13% 64
2017
Q2 		$1.1M Sell
27,646
-5,808
-17% -$223K 0.16% 49
2017
Q1 		$1.23M Buy
33,454
+3,217
+11% +$103K 0.22% 48
2016
Q4 		$964K Buy
30,237
+2,408
+9% +$74.7K 0.29% 57
2016
Q3 		$1.01M Buy
27,829
+3,506
+14% +$97.6K 0.49% 35
2016
Q2 		$552K Sell
24,323
-13,380
-35% -$289K 0.41% 36
2016
Q1 		$709K Buy
+37,703
New +$617K 0.98% 19

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Virtus ETF Advisers's TBPH Position: Q2 2026 in Review

Virtus ETF Advisers increased its Theravance Biopharma (TBPH) stake by 5% in Q2 2026, buying an estimated $7.57K and bringing the position to 9,557 shares worth $162K. The position accounts for 0.06% of the portfolio, ranked #310.

Virtus ETF Advisers first reported a position in TBPH in Q1 2016 and has held it in 39 quarters since. The position peaked at $1.23M in Q1 2017. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Virtus ETF Advisers held 9,557 shares of Theravance Biopharma worth $162K as of Q2 2026.
  • Virtus ETF Advisers bought 457 Theravance Biopharma shares in Q2 2026, an estimated $7.57K.
  • Theravance Biopharma made up 0.06% of Virtus ETF Advisers's portfolio in Q2 2026, its #310 holding.
  • Virtus ETF Advisers first reported a position in Theravance Biopharma in Q1 2016 and has held it in 39 quarters since.
  • Virtus ETF Advisers's Theravance Biopharma position peaked at $1.23M in Q1 2017.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.